---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-161151"
form_type: "8-K"
ticker: "TCRX"
cik: "0001783328"
company_name: "TScan Therapeutics, Inc."
filed_at: "2024-06-14T23:59:59+00:00"
generated_at: "2026-06-01T04:22:58.281306+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# TScan Therapeutics appoints Garry Nicholson to board, Stephen Biggar named chair; Barberich retires

## Summary
- Timothy Barberich resigned as director and Chair effective June 12, 2024; no disagreement cited.
- Stephen Biggar, M.D., Ph.D., assumed Chair role; Nicholson appointed to Board effective same date.
- Garry Nicholson brings 35+ years oncology experience, including former President of Pfizer Oncology.
- Stockholders approved Amended 2021 Equity Plan adding 2M shares; non-employee directors granted options for 308,750 shares at $8.88.
- Nicholson receives initial option for 71,250 shares, vesting over one year or next annual meeting.

## SEC filing metadata
- accession: 0001193125-24-161151
- form_type: 8-K
- ticker: TCRX
- cik: 0001783328
- company_name: TScan Therapeutics, Inc.
- filed_at: 2024-06-14T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783328/000119312524161151/0001193125-24-161151-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783328/000119312524161151/d785285d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-161151
- JSON: https://secwatch.observer/filing/0001193125-24-161151.json
- Plain text: https://secwatch.observer/filing/0001193125-24-161151.txt

## Key facts
- Executive change
  Stephen Biggar changed role as Chairman of the Board at TScan Therapeutics, Inc..
  - Action: assumed
  - Role: Chairman of the Board
  source text: Current member of the Board, Stephen Biggar, M.D., Ph.D., assumed the role of Chairman of the Board, effective as of the Effective Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1783328/000119312524161151/0001193125-24-161151-index.htm
- Executive change
  Timothy Barberich resigned as Chairman of the Board and Director at TScan Therapeutics, Inc..
  - Action: resigned
  - Role: Chairman of the Board and Director
  source text: On June 12, 2024 (the “Effective Date”), after the conclusion of the 2024 Annual Meeting of Stockholders (the “Annual Meeting”) of TScan Therapeutics, Inc. (the “Company”), Timothy Barberich, a member and Chairman of the Board of Directors (the “Board”) of the Company, tendered his resignation from the Board and Chairman position thereof, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1783328/000119312524161151/0001193125-24-161151-index.htm
- Executive change
  Garry Nicholson was appointed as Director at TScan Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: On June 12, 2024, the Board appointed Garry Nicholson to the Board, effective as of the Effective Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1783328/000119312524161151/0001193125-24-161151-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.